Jinghao Wang

Jinghao Wang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in Materials Today Bio
Verified
Journal Article
Open access
QXQiaxin Xu
Qiaxin Xu
ZXZeyu Xiao
Zeyu Xiao
QYQianzhi Yang
Qianzhi Yang
TYTingting Yu
Tingting Yu
XDXiujiao Deng
Xiujiao Deng
JWJinghao Wang
Jinghao Wang
A life-threatening illness that poses a serious threat to human health is myocardial infarction. It may result in a significant number of myocardial cells dying, dilated left ventricles, dysfunctional heart function, and ultimately cardiac failure. Based on the development of emerging biomaterials and the lack of clinical treatment methods and cardiac donors for myocardial infarction, hydrogels with good compatibility have been gradually applied to the treatment of myocardial infarction. Specifically, based on the three processes of pathophysiology of myocardial infarction, we summarized various types of hydrogels designed for myocardial tissue engineering in recent years, including natural hydrogels, intelligent hydrogels, growth factors, stem cells, and microRNA-loaded hydrogels. In addition, we also describe the heart patch and preparation techniques that promote the repair of MI heart function. Although most of these hydrogels are still in the preclinical research stage and lack of clinical trials, they have great potential for further application in the future. It is expected that this review will improve our knowledge of and offer fresh approaches to treating myocardial infarction.

26 July 2023 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MYMeixin Yu
Meixin Yu
RWRuxin Wang
Ruxin Wang
LPLing Pei
Ling Pei
XZXiaofang Zhang
Xiaofang Zhang
JWJinjing Wei
Jinjing Wei
LWLihong Wang
Lihong Wang
Aim: We aimed to assess the association between the use of Glucagon-like peptide-1 receptor agonists and the risk of 12 respiratory diseases in patients with type 2 diabetes, obesity, or overweight. Method: The PubMed (MEDLINE), EMBASE, Cochrane Library, and ClinicalTrials.gov databases were searched from the establishment of the database to December 24, 2022. Dichotomous outcomes were analyzed using RR and 95% CI calculated from fixed-effects models. Results: Twenty-eight RCTs were ultimately included for analysis, involving a total of 77,485 participants. Compared to controls, patients with GLP-1RAs have a 14% lower risk of respiratory disease (RR 0.86, 95% CI 0.81–0.93 p < 0.0001), with Semaglutid (RR 0.82, 95% CI 0.68–0.97, p = 0.02), Liraglutide (RR 0.86. 95% CI 0.75–0.98, p = 0.03), Dulaglutide (RR 0.82, 95% CI 0.70–0.96, p = 0.02), Albiglutide (RR 0.93,95% CI 0.79–1.10, p = 0.40), Exenatide (RR 0.93, 95% CI 0.74–1.18, p = 0.55), Lixisenatide (RR 0.83, 95% CI 0.62–1.12, p = 0.22), and Efpeglenatide (RR 0.76, 95% CI 0.46–1.24, p = 0.27). Semaglutide, Liraglutide and Dulaglutide reduce the risk of respiratory diseases by 18%, 14% and 18%, respectively.Trial duration, control type, and indication were not associated with the impact of GLP-1 receptor agonists on overall respiratory disease. Among secondary outcomes, the risk of Pulmonary edema (RR 0.66, 95% CI 0.44–0.98, p = 0.04), and Bronchitis (RR 0.86, 95% CI 0.74–1.00, p = 0.04) was reduced. Conclusion: In conclusion, GLP-1RAs were linked to a lower risk of overall respiratory diseases, especially Pulmonary edema and Bronchitis. In the future, physicians should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases and evaluate the efficacy of GLP-1RAs in the primary and secondary prevention of respiratory diseases. Trial registration CRD42023396138. Graphical

7 December 2023 in Exploration
Verified
Journal Article
Open access
PDF file
XDXiujiao Deng
Xiujiao Deng
JWJinghao Wang
Jinghao Wang
SYShanshan Yu
Shanshan Yu
STSuiyi Tan
Suiyi Tan
TYTingting Yu
Tingting Yu
ZXZeyu Xiao
Zeyu Xiao
Atherosclerosis, a chronic disease associated with metabolism, poses a significant risk to human well‐being. Currently, existing treatments for atherosclerosis lack sufficient efficiency, while the utilization of surface‐modified nanoparticles holds the potential to deliver highly effective therapeutic outcomes. These nanoparticles can target and bind to specific receptors that are abnormally over‐expressed in atherosclerotic conditions. This paper reviews recent research (2018–present) advances in various ligand‐modified nanoparticle systems targeting atherosclerosis by specifically targeting signature molecules in the hope of precise treatment at the molecular level and concludes with a discussion of the challenges and prospects in this field. The intention of this review is to inspire novel concepts for the design and advancement of targeted nanomedicines tailored specifically for the treatment of atherosclerosis.

10 March 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
Jiafu HuangJiafu Huang
Jiafu Huang
DWDandan Wang
Dandan Wang
JWJinghao Wang
Jinghao Wang
Objectives. This systematic review aims to summarize the existing literature on Tai Chi randomized controlled trials (RCTs) and recommend Tai Chi exercise prescriptions for different diseases and populations. Methods. A systematic search for Tai Chi RCTs was conducted in five electronic databases (PubMed, Cochrane Library, EMBASE, EBSCO, and Web of Science) from their inception to December 2019. SPSS 20.0 software and Microsoft Excel 2019 were used to analyze the data, and the risk of bias tool in the RevMan 5.3.5 software was used to evaluate the methodological quality of RCTs. Results. A total of 139 articles were identified, including diseased populations (95, 68.3) and healthy populations (44, 31.7). The diseased populations included the following 10 disease types: musculoskeletal system or connective tissue diseases (34.7), circulatory system diseases (23.2), mental and behavioral disorders (12.6), nervous system diseases (11.6), respiratory system diseases (6.3), endocrine, nutritional or metabolic diseases (5.3), neoplasms (3.2), injury, poisoning and certain other consequences of external causes (1.1), genitourinary system diseases (1.1), and diseases of the eye and adnexa (1.1). Tai Chi exercise prescription was generally classified as moderate intensity. The most commonly applied Tai Chi style was Yang style (92, 66.2), and the most frequently specified Tai Chi form was simplified 24-form Tai Chi (43, 30.9). 12 weeks and 24 weeks, 2-3 times a week, and 60min each time was the most commonly used cycle, frequency, and time of exercise in Tai Chi exercise prescriptions. Conclusions. We recommend the more commonly used Tai Chi exercise prescriptions for different diseases and populations based on clinical evidence of Tai Chi. Further clinical research on Tai Chi should be combined with principles of exercise prescription to conduct large-sample epidemiological studies and long-term prospective follow-up studies to provide more substantive clinical evidence for Tai Chi exercise prescriptions.
1

12 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JXJingwen Xie
Jingwen Xie
XHXiaoyan Huang
Xiaoyan Huang
MGMin Gao
Min Gao
LWLi Wei
Li Wei
RWRuolun Wang
Ruolun Wang
XLXiaoyan Li
Xiaoyan Li
Drug-related problems (DRPs) are common among surgical patients, especially older patients with polypharmacy and underlying diseases. DRPs can potentially lead to morbidity, mortality, and increased treatment costs. The enhanced recovery after surgery (ERAS) system has shown great advantages in managing surgical patients. Medication therapy management for surgical patients (established as “surgical pharmacy” by Guangdong Province Pharmaceutical Association (GDPA)) is an important part of the ERAS system. Improper medication therapy management can lead to serious consequences and even death. In order to reduce DRPs further, and promote the rapid recovery of surgical patients, the need for pharmacists in the ERAS program is even more pressing. However, the medication therapy management services of surgical pharmacy and how surgical pharmacists should participate in ERAS programs are still unclear worldwide. Therefore, this article reviews the main perioperative medical management strategies and precautions from several aspects, including antimicrobial agents, antithrombotic agents, pain medication, nutritional therapy, blood glucose monitoring, blood pressure treatment, fluid management, treatment of nausea and vomiting, and management of postoperative delirium. Additionally, the way surgical pharmacists participate in perioperative medication management, and the relevant medication pathways are explored for optimizing medication therapy management services within the ERAS programs. This study will greatly assist surgical pharmacists’ work, contributing to surgeons accepting that pharmacists have an important role in the multidisciplinary team, benefitting medical workers in treating, counseling, and advocating for their patients, and further improving the effectiveness, safety and economy of medication therapy for patients and promoting patient recovery.

XZXueyan Zhang
Xueyan Zhang
WLWenhao Li
Wenhao Li
JWJinghao Wang
Jinghao Wang
This paper aims to evaluate the effects of exercise intervention on students’ test anxiety with a meta-analysis to serve as a reference to further relevant research. CNKI, Wanfang Data, VIP, The Cochrane Library, PubMed, Web of Science, Scopus, Embase, and EBSCOhost databases were electronically searched from inception to August 2021 in order to identify randomized and non-randomized controlled trials on exercise for treating students’ test anxiety. Two researchers independently screened the study, extracted data, and evaluated the quality of the studies. Meta-analysis was carried out using Review Manager 5.4 software. Among the 4115 articles retrieved, 16 were qualitative analyses, 15 of which were included in the meta-analysis. The meta-analysis showed that exercise intervention effectively alleviated students’ test anxiety when compared with the blank control group. Subgroup analysis showed that a single exercise intervention lasting 10~15 min did not relieve students’ test anxiety. The different scales used in the study are the source of inter-study heterogeneity. In conclusion, twenty minutes of aerobic exercise at any intensity performed two to three times a week for at least four weeks can reduce test anxiety levels. However, this is the minimum level and students should not be limited to the minimum amount of exercise when reducing test anxiety. In addition, exercise combined with psychotherapy can reduce students’ test anxiety better than exercise intervention alone. Future studies should explore the minimum intervention period and whether the shorter intervention period can quickly and effectively reduce students’ test anxiety.